Study Results & Research Projects

Summaries & Associations of Study Results

TR-469 3'-Azido-3'-Deoxythymidine (AZT) (AIDS Initiative)

Print this page Easy Link

http://ntp.niehs.nih.gov/go/6249

Target Organs and Levels of Evidence
NTP Technical Report Number 469

Produced from Chemtrack Database 09/19/01

CHEMICAL/ CAS NUMBER PEER REVIEW DATE PRIMARY USES ROUTE/EXPOSURE LEVELS STUDY LABORATORY
3'-AZIDO-3'-DEOXYTHYMIDINE (AIDS INITIATIVE)
30516-87-1
12/11/96 PYRIMIDINE NUCLEOSIDE ANALOG WITH ANTIVIRAL ACTIVITY USED IN THE TREATMENT OF AIDS (MERCK 1989) Gavage MICE ONLY: 0, 30, 60, OR 120 MG/KG; 50/SEX Southern Research Institute
LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM):
MM: EQUIVOCAL EVIDENCE KIDNEY TUBULAR CELL: ADENOMA 0/50 0/48 0/49 3/50 OR CARCINOMA 0/50 0/48 0/49 1/50 COMBINED 0/50 0/48 0/49 4/50
HARDERIAN GLAND: ADENOMA 3/33 2/50 2/50 10/46 OR CARCINOMA 0/33 3/50 2/50 0/46 COMBINED 3/33 5/50 2/50 10/46
FM: CLEAR EVIDENCE VAGINA: SQUAMOUS CELL CARCINOMA 0/50 0/50 5/50 9/50; SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 5/50 11/50
NON-NEOPLASTIC LESIONS: VAGINA: EPITHELIAL HYPERPLASIA
INTERFERON AD (AIDS INITIATIVE)
INTERFERONAD
12/11/96 EXPERIMENTAL AIDS THERAPY Subcutaneous Injection MICE ONLY: 500 OR 5000 UNITS 3X/WEEK; 50/SEX/GROUP Southern Research Institute
LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM):
INTERFERON AD + 3'-AZIDO-3'-DEOXYTHYMIDINE (AIDS INITIATIVE)
INTAZTCOMB
12/11/96 USED IN THE EXPERIMENTAL TREATMENT OF AIDS Subcutaneous Inj. + Gavage DUAL ROUTES WITH BOTH COMPOUNDS: AZT: 0, 30, 60, OR 120 (GAV) MG/KG; IFN: 500 OR 5000 UNITS 3X/WEEK Southern Research Institute
LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM):
INTERFERON A (AIDS INITIATIVE)
76543-88-9
12/11/96 EXPERIMENTAL AIDS THERAPY, ANTIVIRAL DRUG, ANTINEOPLASTIC AGENT Subcutaneous Injection 5000 UNITS 3X A WEEK; 50/SEX/GROUP Southern Research Institute
LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM):